Author(s): Larson SM, Carrasquillo JA, Cheung NK, Press OW, Larson SM, Carrasquillo JA, Cheung NK, Press OW, Larson SM, Carrasquillo JA, Cheung NK, Press OW, Larson SM, Carrasquillo JA, Cheung NK, Press OW
Abstract Share this page
Abstract The eradication of cancer remains a vexing problem despite recent advances in our understanding of the molecular basis of neoplasia. One therapeutic approach that has demonstrated potential involves the selective targeting of radionuclides to cancer-associated cell surface antigens using monoclonal antibodies. Such radioimmunotherapy (RIT) permits the delivery of a high dose of therapeutic radiation to cancer cells, while minimizing the exposure of normal cells. Although this approach has been investigated for several decades, the cumulative advances in cancer biology, antibody engineering and radiochemistry in the past decade have markedly enhanced the ability of RIT to produce durable remissions of multiple cancer types.
This article was published in Nat Rev Cancer
and referenced in Immunotherapy: Open Access